In the present study, we report the results of the prospective evaluation of detecting T790M in serum/plasma and its correlation with both clinical and radiographic response in patients with lung adenocarcinoma harboring EGFR mutations who were resistant to first- and second-generation TKIs and who were receiving treatment with osimertinib. This evidence concerns the gene EGFR and lung adenocarcinoma.